Sigachi Industries Sets the Gold Standard in Microcrystalline Cellulose
Sigachi Industries Ltd., India’s largest producer of Microcrystalline Cellulose (MCC), continues to set new benchmarks in global pharmaceutical excipients while strategically expanding into Active Pharmaceutical Ingredients (APIs) and specialty chemicals. With robust financial growth, a diversified portfolio, and an expanding global footprint, Sigachi is now powering ahead as a vertically integrated pharmaceutical player.
In FY25, the company posted a 46.21% EBITDA growth and a 25.42% revenue surge to ₹5,003 million, driven by excipient demand, API capacity expansions, and strategic partnerships across 65+ countries. The company has delivered an EBITDA margin of 22.38% and 14.09% PAT for the same period. The year continues Sigachi’s impressive performance over the last five years, where it has tripled core revenues, achieved 28% PAT CAGR, and maintained low debt and strong operating margins.
“FY25 has been a transformative year for Sigachi,” said Mr. Amit Raj Sinha, MD & CEO of Sigachi Industries. “We’ve built on our core strengths in excipients, while laying a strong foundation for future-ready API and specialty chemical capabilities. Our upcoming Orvakal facility marks the beginning of a new chapter in vertical integration, scalability, and regulatory alignment. It will anchor our next phase of growth and enhance our responsiveness to evolving global customer requirements”
Sigachi has received Terms of Reference (ToR) approval from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh, for a cutting-edge Bulk Drugs and Specialty Chemicals facility in Orvakal, Kurnool District.
